Cost Curve

And We're Off: The Next 15 Drugs Up for Medicare 'Negotiations' Have Been Announced

No real surprises: Ozempic/Wegovy tops the list and four cancer meds will go under the microscope

At the Risk of Repetition: It Was Another Quarter of Record Profits for United's PBM Unit

Plus Teva goes after CMS for IRA rules that kneecap generic competition, and the NYT nails another critical 340B story

Hoo Boy, What a Day: An FTC PBM Report, NYT Goes Deep on 340B, #JPM25 Stuff, and More

It's an everything, everywhere, all at once kind of morning ...

Two Ways of Thinking About the First Day of #JPM25

And the median launch price for a new drug *fell* in 2024 ... will people pay as much attention to that meaningless stat as they did to the meaningless increase in 2023?

Ozempic Will Be Up for IRA ‘Negotiation.’ Here Are The Only Four Storylines You’ll See

And a hello from afar to all of you at #JPM25. May your meeting schedule overfloweth

Bloomberg Law Dove Deep on CMS Explanations for 'Negotiated Prices' ... and Found Them Hollow

And a new poll: when will CMS announce the next 15 meds up for price controls?

CMS 'Negotiations' on Ozempic's Price Will Be a Big Deal ... But Stay Skeptical on Predictions

And four reasons why I'm happy to be skipping JPM this year (tomorrow, I'll give four reasons why skipping might be a mistake)

Implementation of the Medicare Prescription Payment Plan Appears to Be Failing

Plus my contribution to the "2025 Advice" series: Ditch the press release and file a lawsuit instead.

Advice on How to Think About a System 'Heading Over a Cliff'

Plus data and insights on "Jan. 1" price changes, thinking on "smoothing", small PBMs in 2025, and more

This Year, Jan. 1 Price Drops Might Be as Interesting as the Price Hikes

Plus some of the 2025 advice you all have sent along (the survey is still live, too!)

'Advice for 2025' Survey Now Live

I Want Your Thoughts: What 2025 Advice Do You Have for Curve Readers?

It's a slow day, but I still managed to find at least one 340B link, because I want to stay on-brand